Angiozyme

Angiozyme is an anti-angiogenic ribozyme.^[1] It is largely being studied in the treatment of kidney cancer. It may prevent the growth of blood vessels from surrounding tissue to the tumor, i.e., angiogenesis. It belongs to the families of drugs called VEGF receptor and angiogenesis inhibitors. Preliminary tests have demonstrated that Angiogenesis has no significant side effects.^[2] It is also known as RPI.4610.

References

^ "Ribozyme Pharmaceuticals Going Into Clinical Trials with Herzyme, Ribozyme Directed Against HER-2". www.bioprocessonline.com. Retrieved 2017-09-21.
^ Weng, D. E.; Usman, N. (March 2001). "Angiozyme: a novel angiogenesis inhibitor". Current Oncology Reports. 3 (2): 141–146. doi:10.1007/s11912-001-0014-7. ISSN 1523-3790. PMID 11177746. S2CID 45576270.

External links

Angiozyme entry in the public domain NCI Dictionary of Cancer Terms

This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.

This oncology article is a stub. You can help Wikipedia by expanding it.

[1] "Ribozyme Pharmaceuticals Going Into Clinical Trials with Herzyme, Ribozyme Directed Against HER-2". www.bioprocessonline.com. Retrieved 2017-09-21.

[2] Weng, D. E.; Usman, N. (March 2001). "Angiozyme: a novel angiogenesis inhibitor". Current Oncology Reports. 3 (2): 141–146. doi:10.1007/s11912-001-0014-7. ISSN 1523-3790. PMID 11177746. S2CID 45576270.

[1]

[2]